Inverse expression states of the BRN2 and MITF transcription factors in melanoma spheres and tumour xenografts regulate the NOTCH pathway
暂无分享,去创建一个
M. Herlyn | M. Herlyn | S. Zabierowski | J. Leonard | E. Hacker | S. Ramakrishnan | D. J. Smit | A. Thurber | R. Sturm | E. C. Sturm | G. Douglas | Amy E. Thurber | Garth Douglas | Sathiya N. Ramakrishnan | Elke Hacker | Richard A. Sturm
[1] K. Hoek,et al. Cancer stem cells versus phenotype‐switching in melanoma , 2010, Pigment cell & melanoma research.
[2] L. Mariani,et al. Heterogeneous phenotype of human melanoma cells with in vitro and in vivo features of tumor-initiating cells. , 2010, The Journal of investigative dermatology.
[3] D. Dembélé,et al. Genome‐wide analysis of POU3F2/BRN2 promoter occupancy in human melanoma cells reveals Kitl as a novel regulated target gene , 2010, Pigment cell & melanoma research.
[4] C. Bertolotto,et al. Fifteen‐year quest for microphthalmia‐associated transcription factor target genes , 2010, Pigment cell & melanoma research.
[5] J. Han,et al. Isolation and Characterization of Spheroid Cells from Human Malignant Melanoma Cell Line WM-266-4 , 2009, Tumor Biology.
[6] E. Sahai,et al. Intravital imaging reveals transient changes in pigment production and Brn2 expression during metastatic melanoma dissemination. , 2009, Cancer research.
[7] Jae‐Hak Park,et al. Zebrafish embryo extracts promote sphere‐forming abilities of human melanoma cell line , 2009, Cancer science.
[8] P. Pollock,et al. Active Notch1 confers a transformed phenotype to primary human melanocytes. , 2009, Cancer research.
[9] R. Sturm,et al. POU domain transcription factors: BRN2 as a regulator of melanocytic growth and tumourigenesis , 2008, Pigment cell & melanoma research.
[10] P. Nuciforo,et al. Brn-2 represses microphthalmia-associated transcription factor expression and marks a distinct subpopulation of microphthalmia-associated transcription factor-negative melanoma cells. , 2008, Cancer research.
[11] N. Hayward,et al. Histologic and epidemiologic correlates of P-MAPK, Brn-2, pRb, p53, and p16 immunostaining in cutaneous melanomas , 2008, Melanoma research.
[12] Wenjun Guo,et al. The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells , 2008, Cell.
[13] A. Cochran,et al. Immunohistochemical characteristics of melanoma , 2008, Journal of cutaneous pathology.
[14] R. Dummer,et al. In vivo switching of human melanoma cells between proliferative and invasive states. , 2008, Cancer research.
[15] Mohamed H. Sayegh,et al. Identification of cells initiating human melanomas , 2008, Nature.
[16] B. Gardiner,et al. Osteonectin downregulates E‐cadherin, induces Osteopontin and Focal adhesion kinase activity stimulating an invasive melanoma phenotype , 2007, International journal of cancer.
[17] M. Herlyn,et al. The many faces of Notch signaling in skin-derived cells. , 2007, Pigment cell research.
[18] R. Sturm,et al. Post-transcriptional regulation of melanin biosynthetic enzymes by cAMP and resveratrol in human melanocytes. , 2007, The Journal of investigative dermatology.
[19] K. Sneppen,et al. Theoretical Analysis of Epigenetic Cell Memory by Nucleosome Modification , 2007, Cell.
[20] N. Hayward,et al. Confirmation of a BRAF mutation-associated gene expression signature in melanoma. , 2007, Pigment cell research.
[21] A. Sánchez-Aguilera,et al. A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis. , 2007, Cancer research.
[22] Mary J. C. Hendrix,et al. Reprogramming metastatic tumour cells with embryonic microenvironments , 2007, Nature Reviews Cancer.
[23] Jane Goodall,et al. Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. , 2006, Genes & development.
[24] L. Nguyen,et al. Proneural bHLH and Brn proteins coregulate a neurogenic program through cooperative binding to a conserved DNA motif. , 2006, Developmental cell.
[25] Keith T Flaherty,et al. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases , 2006, Molecular Cancer Therapeutics.
[26] D. Elder,et al. A tumorigenic subpopulation with stem cell properties in melanomas. , 2005, Cancer research.
[27] R. Sturm,et al. Co-expression of SOX9 and SOX10 during melanocytic differentiation in vitro. , 2005, Experimental cell research.
[28] Markus Ringnér,et al. Microarray expression profiling in melanoma reveals a BRAF mutation signature , 2004, Oncogene.
[29] M. Herlyn,et al. Human melanoblasts in culture: expression of BRN2 and synergistic regulation by fibroblast growth factor-2, stem cell factor, and endothelin-3. , 2003, The Journal of investigative dermatology.
[30] S. Saule,et al. Microphthalmia transcription factor analysis in posterior uveal melanomas. , 2003, Experimental eye research.
[31] P. Parsons,et al. Redox regulation of Brn-2/N-Oct-3 POU domain DNA binding activity and proteolytic formation of N-Oct-5 during melanoma cell nuclear extraction , 1998, Melanoma research.
[32] G. Sutherland,et al. The brn-2 gene regulates the melanocytic phenotype and tumorigenic potential of human melanoma cells. , 1995, Oncogene.
[33] F. Real,et al. Phenotypic heterogeneity of melanoma. Relation to the differentiation program of melanoma cells , 1987, The Journal of experimental medicine.
[34] Mark Shackleton,et al. Efficient tumour formation by single human melanoma cells , 2008 .
[35] P. Parsons,et al. BRN2 in melanocytic cell development, differentiation, and transformation , 2006 .
[36] V. Hearing,et al. From Melanocytes to Melanoma , 2006 .
[37] A. Houghton,et al. Phenotypic heterogeneity of melanoma. , 1988, Progress in clinical and biological research.
[38] Davis Lj,et al. Phenotypic heterogeneity of melanoma. , 1988 .